Brazil accuses Lilly of delaying generics; Amazon meets with FDA, but why?;

@FiercePharma: Top-read news in FP Thurs: Pfizer eyes Actavis in backup plan to another AstraZeneca bid. Article | Follow @FiercePharma

@TracyStaton: ICYMI this week: CEO on the house that Victoza built and the future of diabetes R&D. Report | Follow @TracyStaton

@EricPFierce: DEA tightens prescribing, limits refills on opioid combo pills like #Vicodin. Story | Follow @EricPFierce

@CarlyHFierce: ICYMI earlier - Report: Takeda's dengue jab will be nipping at Sanofi's heels by 2020. Article | Follow @CarlyHFierce

> Eli Lilly ($LLY) has been accused in Brazil of filing unnecessary lititgation to try to hold off generic competition to a drug. Report

> The European Medicines Agency has agreed to review Cubist Pharmaceuticals' ($CBST) investigational antibiotic ceftolozane/tazobactam for urinary tract and abdominal infections. Release

> Mylan ($MYL) has launched a generic version of Upsher-Smith's Klor-Con for low potassium. Release

> A study from the Canadian Health Policy Institute says that the longer time that Canada takes to approve drugs, compared to the EU, has not resulted in a fewer risks for residents. Report

Medical Device News

@FierceMedDev: Claret Medical ropes in $18M to develop cerebral protection system for TAVR procedures. ICYMI yesterday | Follow @FierceMedDev

@VarunSaxena2: UPDATED with table of deadlines: FDA clarifies UDI requirements with new guidance. Story | Follow @VarunSaxena2

@EmilyWFierce: Pruning of synapses in brain could provide clues to how autism develops in children, say scientists. More from the NYT | Follow @EmilyWFierce

> Google Ventures, Kleiner Perkins back enterprise wearables startup. More

> FDA clears AliveCor smartphone plug-in heart monitor to detect atrial fibrillation. Article

> Claret Medical ropes in $18M to develop cerebral protection system for TAVR procedures. Story

Biotech News

@FierceBiotech: Low levels of enzyme in Alzheimer's brains suggest new drug target. More from FierceBiotech Research | Follow @FierceBiotech

@JohnCFierce: ICYMI yesterday: J&J, AstraZeneca and Sanofi join Illumina to create a pan-cancer test. Report | Follow @JohnCFierce

@DamianFierce: A glimpse at the glamorous hedonism that runs rampant in Big Pharma. Image | Follow @DamianFierce

@EmilyMFierce: Parents more likely to vaccinate kids against measles when child's, not society's, benefits are stressed. FierceVaccines story | Follow @EmilyMFierce

> Pfizer-AstraZeneca sequel could hit theaters next week. Article

> Cubist nears another big antibiotic approval as M&A rumors simmer. Story

> Israel's NeuroDerm banks $16M to advance its Parkinson's pump. More

And Finally... Speculation about why Amazon ($AMZN) officials met with the FDA ranges from the retailer wanting to sell FDA regulated products online to doing something itself in the mobile healthcare arena. Story

Suggested Articles

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.

Alexion and Amgen reached a deal to put off a biosimilar challenger to Alexion's blockbuster rare disease med Soliris until March 2025.

A top adviser for the Trump administration is calling on Congress to push for more manufacturing in Puerto Rico.